Trisulfide modification impacts the reduction step in antibody-drug conjugation process

Bioconjugate Chemistry

Volumn 24, Issue 7, 2013, Pages 1154-1160

  Cumnock, Katherine ^a   Tully, Timothy ^a   Cornell, Christopher ^a   Hutchinson, Matthew ^a   Gorrell, Jeffrey ^a   Skidmore, Ken ^a   Chen, Yan ^a   Jacobson, Fredric ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; COVALENT BONDS; MONOCLONAL ANTIBODIES; PHOSPHORUS COMPOUNDS; REDUCTION;

% REDUCTIONS; ANTIBODY DRUGS; ANTIBODY-DRUG CONJUGATES; CONJUGATION PROCESS; COVALENTLY BOUND; CYTOTOXIC DRUGS; INTERCHAIN DISULFIDE BONDS; REACTION STOICHIOMETRY; REDUCTANTS; TRIS(2 CARBOXYETHYL)PHOSPHINE;

SULFUR COMPOUNDS;

ANTIBODY CONJUGATE; CYSTEINE; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; THIOL; TRIS(2 CARBOXYETHYL)PHOSPHINE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DISULFIDE BOND; DRUG CONJUGATION; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; PH; PROTON NUCLEAR MAGNETIC RESONANCE; REDUCTION KINETICS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STOICHIOMETRY; TEMPERATURE;

EID: 84880373912     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc4000299     Document Type: Article

References (22)

1. Chari, R. V. J. (2008) Targeted cancer therapy: Conferring specificity to cytotoxic drugs Acc. Chem. Res. 41, 98-107
2. Wu, A. M. and Senter, P. D. (2005) Arming antibodies: Prospects and challenges for immunoconjugates Nat. Biotechnol. 23, 1137-1146
3. DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Evans, D. Y., and Damle, N. K. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia Leukemia 21, 2240-2245
4. Phillips, G. D. L., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., Wong, W. L. T., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., and Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with Trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68, 9280-9290
5. Katz, J., Janick, J. E., and Younes, A. (2011) Brentuximab Vedotin (SGN-35) Clin. Cancer Res. 17, 6428-6436
6. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. S., Wong, W. L., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-932
7. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-7070
8. Wakankar, A., Chen, Y., Gokarn, Y., and Jacobson, F. S. (2011) Analytical methods for physicochemical characterization of antibody drug conjugates mAbs 3, 161-172
9. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-784
10. Burns, J. A., Butler, J. C., Moran, J., and Whitesides, G. M. (1991) Selective reduction of disulfides by Tris(2-carboxyethyl)phosphine J. Org. Chem. 56, 2648-2650
11. Getz, E. B., Xiao, M., Chakrabarty, T., Cooke, R., and Selvin, P. R. (1999) A comparison between the sulfhydryl reductants Tris(2-carboxyethyl) phosphine and Dithiothreitol for use in protein biochemistry Anal. Biochem. 273, 73-80
12. Gu, S., Wen, D., Weinreb, P. H., Sun, Y., Zhang, L., Foley, S. F., Kshirsagar, R., Evans, D., Mi, S., Meier, W., and Pepinsky, R. B. (2010) Characterization of trisulfide modification in antibodies Anal. Biochem. 400, 89-98
13. Jespersen, A. M., Christensen, T., Klausen, N. K., Nielsen, P. F., and Sorensen, H. H. (1994) Characterization of a trisulphide derivative of biosynthetic human growth hormone produced in Escherichia coli Eur. J. Biochem. 219, 365-373
14. Canova-Davis, E., Baldonado, I. P., Chloupek, R. C., Ling, V. T., Gehant, R., Olson, K., and Gillece-Castro, B. L. (1996) Confirmation by mass spectrometry of a trisulfide variant in methionyl human growth hormone biosynthesized in Escherichia coli Anal. Chem. 68, 4044-4051
15. Breton, J., Avanzi, N., Valsasina, B., Sgarella, L., La Fiura, A., Breme, U., Orsini, G., Wenisch, E., and Righetti, P. G. (1995) Detection of traces of a trisulphide derivative in the preparation of a recombinant truncated interleukin-6 mutein J. Chromatogr., A 709, 135-146
16. Okado-Matsumoto, A., Guan, Z., and Fridovich, I. (2006) Modification of Cysteine 111 in human Cu,Zn-superoxide dismutase Free Radical Biol. Med. 41, 1837-1846
17. Pristatsky, P., Cohen, S. L., Krantz, D., Acevedo, J., Ionescu, R., and Vlasak, J. (2009) Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody Anal. Chem. 81, 6148-6155
18. Harpp, D. N. and Smith, R. A. (1982) Sulfur-sulfur bond cleavage processes. Selective desulfurization of trisulfides J. Am. Chem. Soc. 104, 6045-6053
19. Evans, D., Pepinsky, R. B., Wen, D., Kshirsagar, R. R., and Lucas, K. (2011) Methods of preventing and removing trisulfide bonds. PCT/US2010/051189, January 10, 2010.
20. Becker, P. and Christensen, T. (20) 10) Method for preventing formation of trisulfide derivatives of polypeptides. US 2010/0160236 A1, Jun 24, 2010.
21. Kshirsagar, R., McElearney, K., Gilbert, A., Sinacore, M., and Ryll, T. (2012) Controlling trisulfide modification in recombinant monoclonal antibody produced in fed-batch cell culture Biotechnol. Bioeng. 109, 2523-253
22. Sun, M. M., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., and Alley, S. C. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjugate Chem. 16, 1282-1290